FDA CMND-100 coverage for business development, investment, and market access teams
Earlier
High impact NewsApr 21, 2026
Clearmind Medicine CMND-100 Meets Primary Safety Endpoint in Alcohol Use Disorder Trial
Alcohol Use Disorder (AUD) · 3 min
Dr. Sarah MitchellHigh impact NewsApr 15, 2026
Clearmind Medicine's CMND-100 Meets Primary Endpoint in Phase I/IIa Trial for Alcohol Use Disorder
FDA · Alcohol Use Disorder (AUD) · 3 min
James Chen, PharmDPopular topics
- Drug Approvals 1,128 articles
- Clinical Trials 634 articles
- Regulatory Updates 687 articles
- FDA News 502 articles
- Press Releases 443 articles
- Oncology 443 articles
- Rare Diseases 141 articles
Explore intelligence
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways